Ortelius asks Surgery Partners to refresh board

Surgery Partners, Inc. (NASDAQ: SGRY) reported its fourth-quarter and full-year 2025 financial results on March 2, 2026, revealing total revenue of approximately $3.3 billion and Adjusted EBITDA of $526.2 million for the year. However, the company acknowledged that its fourth-quarter performance “did not meet our expectations”. Following this disclosure, Surgery Partners’ shares experienced a significant decline as investors reacted to the reported results and management commentary.

Johnson Fistel, PLLP, a securities law firm, has announced an investigation into potential claims against Surgery Partners’ executive officers, focusing on compliance with federal securities laws and the possibility of recovering investor losses. The firm invites shareholders who purchased Surgery Partners securities and incurred losses to contact its team for further information. Johnson Fistel, recognized as one of the top plaintiff law firms in the U.S., has previously secured over $90 million in recoveries for clients.

The investigation follows broader market scrutiny of corporate governance and financial transparency, though no specific allegations of misconduct have been publicly detailed at this time. Investors are advised to monitor developments in the case and the company’s ongoing operations. Surgery Partners has not yet issued a formal response to the legal inquiry.

Johnson Fistel, PLLP's investigation into Surgery Partners, Inc. (NASDAQ: SGRY) is detailed in its March 4, 2026, announcement.